Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a First-Line Tumor Necrosis Factor Inhibitor in the United States

By afschroeder • November 15, 2025

Charles-Schoeman C, Zueger P, McDearmon-Blondell E, Fang S, Peng Y, Oishi T, Jain M, Tesser J. Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a First-Line Tumor Necrosis Factor Inhibitor in the United States. Rheumatol Ther. 2025 Nov 14. doi: 10.1007/s40744-025-00808-z. Epub ahead of print. PMID: 41239038.

Tags: Biologic disease-modifying antirheumatic drug(bDMARD), Clinical Disease Activity Index(CDAI), Publications, Rheumatoid arthritis(RA), Rheumatology, Tumor necrosis factor inhibitor(TNFi)

Forearm BMD predicts fracture independently of FRAX

Kanis JA, Johansson H, Harvey NC, Lorentzon M, Cauley JA, Crandall CJ, Huisman M, Khosla S, Kwok T, Mellström D, Orwoll ES, van Schoor NM,[...]

Ethical Challenges of Extracorporeal Membrane Oxygenation: Enhanced Recovery After Surgery Cardiac Society Consensus on Key Issues and Practical Recommendations

Griffee MJ, Kirsch RE, Rubin J, Peeler A, Hayanga JW, Chatterjee S, Dorsey D, Emeruwa IO, Goodwin ML, Rubin EB, Kim BS, Grant MC, Zaaqoq[...]

Systemic Inflammation and Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease

Sandhu AT, Furst A, Rodriguez F, Kalwani N, Maron D, Nallamshetty S, Din N, Zitko K, Khachatourian K, Skaar JR, Tonnu-Mihara I. Systemic Inflammation and[...]